## Marco de Bruyn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9724564/publications.pdf

Version: 2024-02-01

186265 214800 3,251 49 28 47 citations h-index g-index papers 51 51 51 4433 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Tumor-infiltrating lymphocytes in the immunotherapy era. Cellular and Molecular Immunology, 2021, 18, 842-859.	10.5	403
2	Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. Journal of Clinical Oncology, 2020, 38, 3388-3397.	1.6	398
3	<i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clinical Cancer Research, 2015, 21, 3347-3355.	<b>7.</b> O	249
4	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology and Hepatology, 2016, 1, 207-216.	8.1	227
5	A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. Cancer Immunology Research, 2019, 7, 784-796.	3.4	141
6	cGAS–STING drives the IL-6-dependent survival of chromosomally instable cancers. Nature, 2022, 607, 366-373.	27.8	132
7	CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. European Journal of Cancer, 2016, 60, 1-11.	2.8	125
8	Therapeutic potential of Galectinâ€9 in human disease. Medicinal Research Reviews, 2013, 33, E102-26.	10.5	120
9	MAPK pathway activity plays a key role in PD‣1 expression of lung adenocarcinoma cells. Journal of Pathology, 2019, 249, 52-64.	4.5	117
10	CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. Oncolmmunology, 2017, 6, e1338230.	4.6	116
11	Immunological profiling of molecularly classified high-risk endometrial cancers identifies <i>POLE</i> -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncolmmunology, 2017, 6, e1264565.	4.6	102
12	Carbon monoxide-Releasing Molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in rats. BMC Gastroenterology, 2010, 10, 42.	2.0	80
13	CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy. Oncotarget, 2016, 7, 75130-75144.	1.8	64
14	Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Molecular Cancer, 2010, 9, 301.	19.2	58
15	Frequency of Th $17$ CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects. Arthritis Research and Therapy, 2011, 13, R208.	3.5	56
16	Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2016, 22, 714-724.	7.0	51
17	CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination. Multiple Sclerosis and Related Disorders, 2014, 3, 650-658.	2.0	49
18	The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. Autophagy, 2015, 11, 1373-1388.	9.1	49

#	Article	IF	CITATIONS
19	First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers. Molecular Therapy, 2021, 29, 611-625.	8.2	48
20	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nature Communications, 2022, 13, 1373.	12.8	47
21	Antibody-based fusion proteins to target death receptors in cancer. Cancer Letters, 2013, 332, 175-183.	7.2	46
22	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. Cancer Immunology Research, 2020, 8, 1508-1519.	3.4	45
23	Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. Clinical Cancer Research, 2020, 26, 5400-5410.	7.0	41
24	Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells. Journal of Molecular Medicine, 2008, 86, 909-924.	3.9	37
25	The Ever-Expanding Immunomodulatory Role of Calreticulin in Cancer Immunity. Frontiers in Oncology, 2015, 5, 35.	2.8	36
26	The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma Cells. Journal of Investigative Dermatology, 2012, 132, 2302-2305.	0.7	35
27	Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. Modern Pathology, 2018, 31, 1851-1861.	5.5	35
28	Cell Surface Delivery of TRAIL Strongly Augments the Tumoricidal Activity of T Cells. Clinical Cancer Research, 2011, 17, 5626-5637.	7.0	32
29	Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists. ACS Medicinal Chemistry Letters, 2021, 12, 768-773.	2.8	30
30	Potent Systemic Anticancer Activity of Adenovirally Expressed EGFR-Selective TRAIL Fusion Protein. Molecular Therapy, 2008, 16, 1919-1926.	8.2	29
31	Microsatellite instability derived <i>JAK1</i> frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer. Oncotarget, 2016, 7, 39885-39893.	1.8	29
32	Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis. Nature Communications, 2019, 10, 533.	12.8	26
33	C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity. MAbs, 2015, 7, 321-330.	5.2	22
34	Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death. Molecular Cancer, 2014, 13, 85.	19.2	21
35	Both exposure to a novel context and associative learning induce an upregulation of AKAP150 protein in mouse hippocampus. Neurobiology of Learning and Memory, 2007, 87, 693-696.	1.9	17
36	CD20 <sup>+</sup> T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. Oncolmmunology, 2015, 4, e999536.	4.6	17

#	Article	IF	CITATIONS
37	Selective elimination of pathogenic synovial fluid T-cells from Rheumatoid Arthritis and Juvenile Idiopathic Arthritis by targeted activation of Fas-apoptotic signaling. Immunology Letters, 2011, 138, 161-168.	2.5	15
38	Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study. Oncology, 2018, 95, 100-108.	1.9	15
39	Transcriptional Activity and Stability of CD39+CD103+CD8+ T Cells in Human High-Grade Endometrial Cancer. International Journal of Molecular Sciences, 2020, 21, 3770.	4.1	13
40	Antigen-specific active immunotherapy for ovarian cancer. The Cochrane Library, 2018, 9, CD007287.	2.8	11
41	Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome. Oncolmmunology, 2020, 9, 1760705.	4.6	11
42	CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties. Scientific Reports, 2021, 11, 20499.	3.3	11
43	Association of homozygous variants of STING1 with outcome in human cervical cancer. Cancer Science, 2021, 112, 61-71.	3.9	11
44	Combined STING levels and CD103+ T cell infiltration have significant prognostic implications for patients with cervical cancer. Oncolmmunology, 2021, 10, 1936391.	4.6	9
45	Automated causal inference in application to randomized controlled clinical trials. Nature Machine Intelligence, 2022, 4, 436-444.	16.0	8
46	In Vivo Responses of Human A375M Melanoma to a $\ddot{l}f$ Ligand: 18F-FDG PET Imaging. Journal of Nuclear Medicine, 2013, 54, 1613-1620.	5.0	7
47	Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial Cancer. Cancers, 2022, 14, 1924.	3.7	5
48	$171\hat{a}\in$ Preclinical studies support therapeutic application of the leukemic cell-based cancer relapse vaccine DCP-001 in ovarian cancer. , 2020, , .		0
49	Rapid and efficient generation of antigenâ€specific isogenic T cells from cryopreserved blood samples. Immunology and Cell Biology, 2022, 100, 285-295.	2.3	0